Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Doxorubicin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Doxorubicin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxorubicin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Doxorubicin Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aducanumab,Lecanemab
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Ali Rezai
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Aducanumab,Lecanemab
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Ali Rezai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pembrolizumab,Atezolizumab,Cemiplimab,Nivolumab,Iptilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Pembrolizumab,Atezolizumab,Cemiplimab,Nivolumab,Iptilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid HCl,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : SonALAsense
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims at conducting a first-in-human clinical trial in rGBM using SonALAsense's innovative Phase 0 approach to rapidly assess safety, and biological and clinical efficacy of aminolevulinic acid (ALA SDT).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : Aminolevulinic Acid HCl,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : SonALAsense
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Carboplatin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 19, 2020
Lead Product(s) : Carboplatin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carboplatin,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Carboplatin,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable